Project description:Chromatin immunoprecipitation linked to tiling arrays (ChIP-chip) were performed to profile histone H3K9Ac at 22K gene promoters in peripheral blood lymphocytes obtained in 2009-10 from 60 selected DCCT participants being followed in the long-term observational EDIC study. Comparison of histone H3K9Ac at 22K gene promoters in 60 peripheral blood lymphocytes samples obtained from the conventional and intensive therapy DCCT groups
Project description:Chromatin immunoprecipitation linked to tiling arrays (ChIP-chip) were performed to profile histone H3K9Ac at 22K gene promoters in peripheral blood monocytes obtained in 2009-10 from 60 selected DCCT participants being followed in the long-term observational EDIC study. Comparison of histone H3K9Ac at 22K gene promoters in 60 peripheral blood monocytes samples obtained from the conventional and intensive therapy DCCT groups
Project description:Chromatin immunoprecipitation linked to tiling arrays (ChIP-chip) were performed to profile histone H3K9Ac at 22K gene promoters in peripheral blood lymphocytes obtained in 2009-10 from 60 selected DCCT participants being followed in the long-term observational EDIC study.
Project description:Chromatin immunoprecipitation linked to tiling arrays (ChIP-chip) were performed to profile histone H3K9Ac at 22K gene promoters in peripheral blood monocytes obtained in 2009-10 from 60 selected DCCT participants being followed in the long-term observational EDIC study.
Project description:Study the association of DNA-methylation and metabolic memory by examing DNA-methylation alternation between cases (received conventional therapy in DCCT and showing retinopathy or albuminuria progression at EDIC year-10) and Controls(in DCCT intensive treatment group and did not have retinopathy or nephropathy progression during EDIC]
Project description:Study the association of DNA-methylation and metabolic memory by examing DNA-methylation alternation between cases (received conventional therapy in DCCT and showing retinopathy or albuminuria progression at EDIC year-10) and Controls (in DCCT intensive treatment group and did not have retinopathy or nephropathy progression during EDIC).
